U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H43NO18
Molecular Weight 645.6048
Optical Activity UNSPECIFIED
Defined Stereocenters 18 / 18
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACARBOSE

SMILES

C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]3C=C(CO)[C@@H](O)[C@H](O)[C@H]3O

InChI

InChIKey=CEMXHAPUFJOOSV-XGWNLRGSSA-N
InChI=1S/C25H43NO18/c1-7-13(26-9-2-8(3-27)14(33)18(37)15(9)34)17(36)20(39)24(41-7)44-23-12(6-30)42-25(21(40)19(23)38)43-22(11(32)5-29)16(35)10(31)4-28/h2,4,7,9-27,29-40H,3,5-6H2,1H3/t7-,9+,10+,11-,12-,13-,14-,15+,16-,17+,18+,19-,20-,21-,22-,23-,24-,25-/m1/s1

HIDE SMILES / InChI
Molecular Formula C25H43NO18
Molecular Weight 645.6048
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 18 / 18
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Acarbose is an anti-diabetic drug used to treat type 2 diabetes mellitus and, in some countries, prediabetes. Acarbose is an oligosaccharide which is obtained from fermentation processes of a microorganism, Actinoplanes utahensis, and is chemically known as O-4,6-dideoxy¬ 4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]¬ α-D-glucopyranosyl-(1 → 4)-O-α-D-glucopyranosyl-(1 → 4)-D-glucose. Acarbose is a complex oligosaccharide that delays the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. As a consequence of plasma glucose reduction, PRECOSE (acarbose tablets) reduces levels of glycosylated hemoglobin in patients with type 2 diabetes mellitus. Systemic non-enzymatic protein glycosylation, as reflected by levels of glycosylated hemoglobin, is a function of average blood glucose concentration over time. In contrast to sulfonylureas, PRECOSE does not enhance insulin secretion. The antihyperglycemic action of acarbose results from a competitive, reversible inhibition of pancreatic alpha-amylase and membrane-bound intestinal alpha-glucoside hydrolase enzymes. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine, while the membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In diabetic patients, this enzyme inhibition results in a delayed glucose absorption and a lowering of postprandial hyperglycemia. Because its mechanism of action is different, the effect of PRECOSE to enhance glycemic control is additive to that of sulfonylureas, insulin or metformin when used in combination. In addition, PRECOSE diminishes the insulinotropic and weight-increasing effects of sulfonylureas. Acarbose has no inhibitory activity against lactase and consequently would not be expected to induce lactose intolerance.

Approval Year

1995
203
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Inhibitor
8504
Inhibitor
8504
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8583
PRECOSE

Approved Use

Acarbose Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Launch Date

1995
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
49 ng/mL
REVIEW
https://books.google.ru/books?id=QpjsCAAAQBAJ&pg=PA543&lpg=PA543&dq=Acarbose+AUC+human&source=bl&ots=z43vS8W_1j&sig=ACfU3U1iPoHWm_dZPMGsYSpyidnw6GVLYw&hl=ru&sa=X&ved=2ahUKEwiTm4zGzYbnAhVriYsKHcGpAO8Q6AEwAnoECAYQAQ#v=onepage&q=Acarbose%20AUC%20human&f=false
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACARBOSE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.13 μg × h/mL
REVIEW
https://link.springer.com/chapter/10.1007/978-3-642-73583-7_4
0.4 mg/kg single, intravenous
dose: 0.4 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ACARBOSE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.51 μg × h/mL
REVIEW
https://link.springer.com/chapter/10.1007/978-3-642-73583-7_4
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACARBOSE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.55 h
REVIEW
https://link.springer.com/chapter/10.1007/978-3-642-73583-7_4
0.4 mg/kg single, intravenous
dose: 0.4 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ACARBOSE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9839093/
unhealthy, 57.2
Health Status: unhealthy
Age Group: 57.2
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9839093/
Disc. AE: Flatulence, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Flatulence (26%)
Diarrhea (17%)
Abdominal pain (7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9839093/
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Other AEs: Flatulence, Diarrhea...
Other AEs:
Flatulence (68 patients)
Diarrhea (13 patients)
Loose stools (1 patient)
Abdominal pain (4 patients)
Nausea (3 patients)
Constipation (1 patient)
Hypoglycaemic episode (10 patients)
Appetite lost (2 patients)
Weight loss (1 patient)
Burning anal (1 patient)
Heartburn (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
Other AEs: Flatulence, Diarrhoea...
Other AEs:
Flatulence (13.7%)
Diarrhoea (2.2%)
Hypoglycaemia (0.07%)
Function liver abnormal (0.01%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
AEs

AEs

AESignificanceDosePopulation
Diarrhea 17%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9839093/
unhealthy, 57.2
Health Status: unhealthy
Age Group: 57.2
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9839093/
Flatulence 26%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9839093/
unhealthy, 57.2
Health Status: unhealthy
Age Group: 57.2
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9839093/
Abdominal pain 7%
Disc. AE
100 mg 3 times / day multiple, oral
Recommended
Dose: 100 mg, 3 times / day
Route: oral
Route: multiple
Dose: 100 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9839093/
unhealthy, 57.2
Health Status: unhealthy
Age Group: 57.2
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9839093/
Burning anal 1 patient
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Constipation 1 patient
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Heartburn 1 patient
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Loose stools 1 patient
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Weight loss 1 patient
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Hypoglycaemic episode 10 patients
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Diarrhea 13 patients
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Appetite lost 2 patients
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Nausea 3 patients
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Abdominal pain 4 patients
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Flatulence 68 patients
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/11323089/
Function liver abnormal 0.01%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
Hypoglycaemia 0.07%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
Flatulence 13.7%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
Diarrhoea 2.2%
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17532710/
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:2376
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2376
eMolecules
4775595
https://www.emolecules.com/cgi-bin/more?vid=4775595
MolPort
MolPort-002-507-369
https://www.molport.com/shop/molecule-link/MolPort-002-507-369
PubMed

PubMed

TitleDatePubMed
The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
2010-12
Bioinformatic and biochemical studies point to AAGR-1 as the ortholog of human acid alpha-glucosidase in Caenorhabditis elegans.
2010-08
Effects of acarbose on the acceleration of postprandial hyperglycemia-induced pathological changes induced by intermittent hypoxia in lean mice.
2010
The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.
2009-05
Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation.
2008-06
Effects of chronic acarbose treatment on adipocyte insulin responsiveness, serum levels of leptin and adiponectin and hypothalamic NPY expression in obese diabetic Wistar rats.
2008-03
Contribution of mucosal maltase-glucoamylase activities to mouse small intestinal starch alpha-glucogenesis.
2007-07
Acarbose, an alpha-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats.
2006-12-01
Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial.
2004-12
[Acarbose-induced acute hepatitis. Report of two events in the same patient].
2004-08-25
Acarbose attenuates experimental non-alcoholic steatohepatitis.
2004-03-12
Treatment for hyperglycemia promotes pancreatic regeneration in rats without CCK-1 receptor gene expression.
2003-05
Chronic acarbose-feeding increases GLUT1 protein without changing intestinal glucose absorption function.
2002-01-11
Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice.
1998-04
Acarbose reduces blood pressure in sucrose-induced hypertension in rats.
1997-03
Effect of acarbose on glucose homeostasis, lipogenesis and lipogenic enzyme gene expression in adipose tissue of weaned rats.
1993-06
Altered expression of muscle glucose transporter GLUT-4 in diabetic fatty Zucker rats (ZDF/Drt-fa).
1991-12
Patents

Patents

WO2006032011A2
1

Sample Use Guides

In Vivo Use Guide
Curator's Comment: There is no fixed dosage regimen for the management of diabetes mellitus with PRECOSE or any other pharmacologic agent
Dosage of PRECOSE must be individualized on the basis of both effectiveness and tolerance while not exceeding the maximum recommended dose of 100 mg t.i.d. PRECOSE should be taken three times daily at the start (with the first bite) of each main meal. PRECOSE should be started at a low dose,
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: an inhibition of two thirds of alpha-amylase activity can be expected from pharmacologically used doses of acarbose.
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:26:31 GMT 2025
Edited
by admin
on Mon Mar 31 18:26:31 GMT 2025
Record UNII
T58MSI464G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACARBOSE
USAN  
Official Name English
PRECOSE
Preferred Name English
ACARBOSE [MI]
Common Name English
ACARBOSE [ORANGE BOOK]
Common Name English
ACARBOSE [MART.]
Common Name English
ACARBOSE [VANDF]
Common Name English
ACARBOSE [USP MONOGRAPH]
Common Name English
O-4,6-DIDEOXY-4-(((1S,4R,5S,6S)-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)-2-CYCLOHEXEN-1-YL)AMINO).ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-D-GLUCOPYRANOSE
Common Name English
ACARBOSE [USAN]
Common Name English
ACARBOSE [EP MONOGRAPH]
Common Name English
ACARBOSE [EP IMPURITY]
Common Name English
NSC-758915
Code English
ACARBOSE [USP-RS]
Common Name English
BAY G 5421
Code English
ACARBOSE [JAN]
Common Name English
D-GLUCOSE, O-4,6-DIDEOXY-4-(((1S-(1.ALPHA.,4.ALPHA.,5.BETA.,6.ALPHA.))-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)-2-CYCLOHEXEN-1-YL)AMINO)-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-
Common Name English
Acarbose [WHO-DD]
Common Name English
acarbose [INN]
Common Name English
BAY-G-5421
Code English
O-4,6-DIDEOXY-4-(((1S,4R,5S,6S)-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)-2-CYCLOHEXEN-1-YL)AMINO)-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-D-GLUCOSE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2846
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
NDF-RT N0000000166
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
WHO-VATC QA10BF01
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
NCI_THESAURUS C29711
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
LIVERTOX NBK548181
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
WHO-ATC A10BF01
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
NDF-RT N0000175559
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
WHO-ATC A10BD17
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
Code System Code Type Description
MERCK INDEX
m1289
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY Merck Index
CHEBI
84363
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
INN
4527
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
EPA CompTox
DTXSID8046034
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
DRUG CENTRAL
39
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
WIKIPEDIA
ACARBOSE
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
MESH
D020909
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
NCI_THESAURUS
C983
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
FDA UNII
T58MSI464G
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
RS_ITEM_NUM
1000521
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
CAS
56180-94-0
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
USAN
T-9
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
ECHA (EC/EINECS)
260-030-7
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
IUPHAR
6791
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
LACTMED
Acarbose
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
EVMPD
SUB07368MIG
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
ChEMBL
CHEMBL1566
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
DRUG BANK
DB00284
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
SMS_ID
100000092276
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
PUBCHEM
9811704
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
HSDB
56180-94-0
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
CHEBI
2376
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
RXCUI
16681
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY RxNorm
DAILYMED
T58MSI464G
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
NSC
758915
Created by admin on Mon Mar 31 18:26:31 GMT 2025 , Edited by admin on Mon Mar 31 18:26:31 GMT 2025
PRIMARY
Related Record Type Details
PANCREATIC ALPHA-AMYLASE
TARGET -> INHIBITOR
Acarbose acts locally within the gastrointestinal tract, this low systemic bioavailability of parent compound.
IC50
GLUCAGON-LIKE PEPTIDE 1
TARGET->ACTIVATOR OF EXPRESSION
Acarbose treatment stimulates postprandial GLP-1 secretion in patients with type 2 diabetes. Dependent on dose and saccharide or polysaccharide present. A single dose of 100 mg acarbose during an oral sucrose (disaccharide) load resulted in elevated GLP-1 levels compared to placebo (8, 10, 28, 29) whereas no effect was seen during oral glucose tolerance test (24), emphasizing that acarbose needs relevant carbohydrates to ‘act on’ in order to increase GLP-1 secretion. A single dose of 100 mg acarbose during an oral sucrose (disaccharide) load resulted in elevated GLP-1 levels compared to placebo (8, 10, 28, 29) whereas no effect was seen during oral glucose tolerance test (24), emphasizing that acarbose needs relevant carbohydrates to ‘act on’ in order to increase GLP-1 secretion.
Isomaltase, human intestinal
TARGET -> INHIBITOR
Sucrase, human intestinal
TARGET -> INHIBITOR
Related Record Type Details
Structure of ACARVIOSINE-GLUCOSE
METABOLITE ACTIVE -> PARENT
Acarbose is exclusively metabolized within the gastrointestinal tract, principally by intestinal bacteria.
MAJOR
URINE
Related Record Type Details
Structure of O-4,6-DIDEOXY-4-(((1S,4R,5S,6S)-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)-2-CYCLOHEXEN-1-YL)AMINO)-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-D-FRUCTOSE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
Structure of O-4,6-DIDEOXY-4-(((1S,4R,5S,6S)-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)CYCLOHEX-2-ENYL)AMINO)-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-D-ARABINO-HEX-2-ULOPYRANOSE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
Structure of ACARBOSE IMPURITY F
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
Structure of D-GLUCOPYRANOSYL O-4,6-DIDEOXY-4-(((1S,4R,5S,6S)-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)CYCLOHEX-2-ENYL)AMINO)-D-GLUCOPYRANOSYL-(1->4)-O-D-GLUCOPYRANOSYL-(1->4)-O-D-GLUCOPYRANOSIDE (D-GLUCOPYRANOSYL-ACARBOSIDE)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
Structure of (1R,4R,5S,6R)-4,5,6-TRIHYDROXY-2-(HYDROXYMETHYL)CYCLOHEX-2-ENYL 4-O-(4,6-DIDEOXY-4-(((1S,4R,5S,6S)-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)CYCLOHEX-2-ENYL)AMINO)-.ALPHA.-D-GLUCOPYRANOSYL)-.ALPHA.-D-GLUCOPYRANOSIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Other
Structure of .ALPHA.-D-GLUCOPYRANOSYL O-4,6-DIDEOXY-4-(((1S,4R,5S,6S)-4,5,6-TRIHYDROXY-3-(HYDROXYMETHYL)-2-CYCLOHEXEN-1-YL)AMINO)-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-.ALPHA.-D-GLUCOPYRANOSIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of ACARVIOSINE-GLUCOSE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ph.Eur.; USP
Structure of PSEUDOACARBOSE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-nitroso-acarbose
IMPURITY -> PARENT
Related Record Type Details
Structure of ACARBOSE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966